[go: up one dir, main page]

EE03770B1 - Pürido[2,3-d]pürimidiinid kui türosiinkinaas-valgu poolt vahendatava rakkude proliferatsiooni inhibiitorid, farmatseutiline kompositsioon, kasutamine - Google Patents

Pürido[2,3-d]pürimidiinid kui türosiinkinaas-valgu poolt vahendatava rakkude proliferatsiooni inhibiitorid, farmatseutiline kompositsioon, kasutamine

Info

Publication number
EE03770B1
EE03770B1 EE9700274A EE9700274A EE03770B1 EE 03770 B1 EE03770 B1 EE 03770B1 EE 9700274 A EE9700274 A EE 9700274A EE 9700274 A EE9700274 A EE 9700274A EE 03770 B1 EE03770 B1 EE 03770B1
Authority
EE
Estonia
Prior art keywords
inhibitors
pyrido
pyrimidines
pharmaceutical composition
cell proliferation
Prior art date
Application number
EE9700274A
Other languages
English (en)
Other versions
EE9700274A (et
Inventor
John Blankley Clifton
Harris Boschelli Diane
Marian Doherty Annette
Marino Hamby James
Lee Panek Robert
Klutchko Sylvester
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,294 external-priority patent/US5620981A/en
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE9700274A publication Critical patent/EE9700274A/et
Publication of EE03770B1 publication Critical patent/EE03770B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EE9700274A 1995-05-03 1996-04-26 Pürido[2,3-d]pürimidiinid kui türosiinkinaas-valgu poolt vahendatava rakkude proliferatsiooni inhibiitorid, farmatseutiline kompositsioon, kasutamine EE03770B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/433,294 US5620981A (en) 1995-05-03 1995-05-03 Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US08/611,279 US5733914A (en) 1995-05-03 1996-04-03 Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
PCT/US1996/005819 WO1996034867A1 (en) 1995-05-03 1996-04-26 PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION

Publications (2)

Publication Number Publication Date
EE9700274A EE9700274A (et) 1998-06-15
EE03770B1 true EE03770B1 (et) 2002-06-17

Family

ID=27029804

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700274A EE03770B1 (et) 1995-05-03 1996-04-26 Pürido[2,3-d]pürimidiinid kui türosiinkinaas-valgu poolt vahendatava rakkude proliferatsiooni inhibiitorid, farmatseutiline kompositsioon, kasutamine

Country Status (21)

Country Link
EP (1) EP0823908B1 (et)
JP (1) JP3885116B2 (et)
CN (1) CN1083452C (et)
AT (1) ATE344263T1 (et)
AU (1) AU713727B2 (et)
BG (1) BG62617B1 (et)
CA (1) CA2214219C (et)
CZ (1) CZ288160B6 (et)
DE (1) DE69636671T2 (et)
EA (1) EA000897B1 (et)
EE (1) EE03770B1 (et)
ES (1) ES2274526T3 (et)
GE (1) GEP20002032B (et)
HU (1) HUP9801704A3 (et)
IL (1) IL117923A (et)
MX (1) MX9706529A (et)
NO (1) NO310110B1 (et)
NZ (1) NZ307021A (et)
PL (1) PL184093B1 (et)
SK (1) SK283952B6 (et)
WO (1) WO1996034867A1 (et)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (et) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033977A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
EP1806348A3 (en) * 1997-02-05 2008-01-02 Warner-Lambert Company LLC Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
BR9807305A (pt) * 1997-02-05 2000-05-02 Warner Lambert Co Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9716231D0 (en) * 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
KR20010043829A (ko) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
EP1801112A1 (en) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
EP1123295B1 (en) * 1998-10-23 2004-09-29 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
HUP0203477A3 (en) 1999-10-21 2004-12-28 Hoffmann La Roche Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase, pharmaceutical compositions containing them and their preparations
AU776250B2 (en) 1999-10-21 2004-09-02 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
AU769222B2 (en) 1999-11-05 2004-01-22 Genzyme Corporation Quinazoline derivatives as VEGF inhibitors
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
WO2001042243A2 (en) * 1999-12-08 2001-06-14 Advanced Medicine, Inc. Protein kinase inhibitors
CA2417937A1 (en) 2000-08-04 2002-02-14 Warner-Lambert Company Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
DE60113161T2 (de) 2000-08-04 2006-06-14 Warner Lambert Co Verfahren zur herstellung von 2-(4-pyridyl)amino-6-dialkylolxaphenyl-pyrido(2,3-d)pyrimidon-7-on-derivaten
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
EP1315727B1 (en) * 2000-08-31 2005-06-29 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines
EP1315726A1 (en) * 2000-08-31 2003-06-04 F. Hoffmann-La Roche Ag 7- oxo pyridopyrimidines as inhibitors of cellular proliferation
DE60206363T2 (de) 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
WO2003057165A2 (en) 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
MXPA05001332A (es) 2002-08-06 2005-04-28 Hoffmann La Roche 6-alcoxi-pirido-pirimidinas como inhibidores de cinasa del map p-38.
RS20050363A (sr) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN100420687C (zh) * 2002-12-20 2008-09-24 霍夫曼-拉罗奇有限公司 作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
BRPI0415210A (pt) 2003-10-08 2006-12-05 Irm Llc compostos e composições como inibidores de proteìna cinase
EP1685131B1 (en) 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
BRPI0507852A (pt) * 2004-02-18 2007-07-10 Warner Lambert Co 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510770A (ja) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
CA2622725A1 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
WO2007044813A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
JP5480503B2 (ja) * 2005-10-07 2014-04-23 エクセリクシス， インク． ＰＩ３Ｋαのピリドピリミジノン型阻害剤
FR2896246B1 (fr) * 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
ES2329419T3 (es) 2006-01-31 2009-11-25 F. Hoffmann-La Roche Ag 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2076266A2 (en) * 2006-05-31 2009-07-08 The Board of Trustees of the Leland Stanford Junior University Method of treating inflammatory diseases using tyroskine kinase inhibitors
PL2074122T3 (pl) 2006-09-15 2011-10-31 Pfizer Prod Inc Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2008127712A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2008127678A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
EP3098223A1 (en) 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
UY32153A (es) 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
MX2012004157A (es) 2009-10-09 2012-08-03 Afraxis Inc 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
SG10201601711SA (en) 2011-03-04 2016-04-28 Newgen Therapeutics Inc Alkyne Substituted Quinazoline Compound And Methods Of Use
MX2013011518A (es) * 2011-04-08 2014-06-04 Afraxis Holdings Inc 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer.
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
AU2013259551B2 (en) * 2012-05-09 2017-11-02 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
ES2916220T3 (es) * 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
WO2014052365A1 (en) 2012-09-26 2014-04-03 Mannkind Corporation Multiple kinase pathway inhibitors
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
SMT202200292T1 (it) 2013-10-25 2022-09-14 Blueprint Medicines Corp Inibitori del recettore del fattore di crescita dei fibroblasti
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN106749173A (zh) * 2016-11-25 2017-05-31 吉林化工学院 一种嘧啶联吡啶类化合物的制备方法
US11174255B2 (en) 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
US12516055B2 (en) 2019-05-16 2026-01-06 Trustees Of Tufts College Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
KR102329720B1 (ko) 2019-08-30 2021-11-23 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
WO2023177356A2 (en) * 2022-03-18 2023-09-21 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
EP0584222B1 (en) * 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FR2706898B1 (et) * 1993-06-25 1995-09-08 Union Pharma Scient Appl
ATE190978T1 (de) * 1994-11-14 2000-04-15 Warner Lambert Co 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung

Also Published As

Publication number Publication date
AU5576996A (en) 1996-11-21
ATE344263T1 (de) 2006-11-15
SK141097A3 (en) 1998-07-08
CA2214219C (en) 2008-09-30
BG102003A (en) 1998-12-30
CN1083452C (zh) 2002-04-24
IL117923A (en) 2000-06-01
BG62617B1 (bg) 2000-03-31
IL117923A0 (en) 1996-08-04
CA2214219A1 (en) 1996-11-07
HUP9801704A3 (en) 1999-03-01
GEP20002032B (en) 2000-04-10
SK283952B6 (sk) 2004-06-08
WO1996034867A1 (en) 1996-11-07
ES2274526T3 (es) 2007-05-16
CZ327597A3 (cs) 1998-03-18
JP3885116B2 (ja) 2007-02-21
NO310110B1 (no) 2001-05-21
JPH11504922A (ja) 1999-05-11
AU713727B2 (en) 1999-12-09
CN1183099A (zh) 1998-05-27
EA000897B1 (ru) 2000-06-26
NZ307021A (en) 2001-04-27
EP0823908B1 (en) 2006-11-02
DE69636671D1 (de) 2006-12-14
HUP9801704A2 (hu) 1998-11-30
EA199700356A1 (ru) 1998-06-25
PL323089A1 (en) 1998-03-02
NO975033D0 (no) 1997-10-31
EE9700274A (et) 1998-06-15
MX9706529A (es) 1997-11-29
EP0823908A1 (en) 1998-02-18
CZ288160B6 (en) 2001-05-16
PL184093B1 (pl) 2002-08-30
DE69636671T2 (de) 2007-08-30
NO975033L (no) 1997-10-31

Similar Documents

Publication Publication Date Title
EE03770B1 (et) Pürido[2,3-d]pürimidiinid kui türosiinkinaas-valgu poolt vahendatava rakkude proliferatsiooni inhibiitorid, farmatseutiline kompositsioon, kasutamine
FI971953A0 (fi) Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6-aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
CA2291222A1 (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
TR199900048T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
BR9708640B1 (pt) inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo.
ATE244719T1 (de) N-7 heterocyclyl-pyrrolo( 2,3-d)pyrimidine und ihre verwendung
MY141144A (en) 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
DK0938486T3 (da) Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
AR007857A1 (es) Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

MM4A Lapsed by not paying the annual fees

Effective date: 20060426